AU7R-104

P1, N=9, Terminated, Aurigene Discovery Technologies Limited | N=42 --> 9 | Trial completion date: Jan 2027 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Feb 2026; Patient recruitment problems

P1, N=42, Recruiting, Aurigene Discovery Technologies Limited

In summary, we have identified a novel covalent FABP5 inhibitor with optimized properties that showed anti-tumor activity in in vitro and in vivo models with acceptable safety profile. The data presented here strongly support clinical development of AUR104.